Preliminary clinical activity of TP-0903 in relapsed or refractory acute myeloid leukemia with FLT3-ITD mutations
Acute myeloid leukemia (AML) patients with FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) experience shorter disease-free survival and high relapse rates even with FLT3 inhibitor therapy. One of the main mechanisms for loss of response is the acquisition of molecular mutations tha...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-04-01
|
| Series: | Frontiers in Hematology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/frhem.2025.1554764/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849710520904450048 |
|---|---|
| author | Bhavana Bhatnagar Daelynn R. Buelow Kaitlyn M. Dvorak-Kornaus Shelley J. Orwick Jae Yoon Jeon Zahra Talebi Amy S. Ruppert James S. Blachly Uma Borate Sharyn D. Baker |
| author_facet | Bhavana Bhatnagar Daelynn R. Buelow Kaitlyn M. Dvorak-Kornaus Shelley J. Orwick Jae Yoon Jeon Zahra Talebi Amy S. Ruppert James S. Blachly Uma Borate Sharyn D. Baker |
| author_sort | Bhavana Bhatnagar |
| collection | DOAJ |
| description | Acute myeloid leukemia (AML) patients with FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) experience shorter disease-free survival and high relapse rates even with FLT3 inhibitor therapy. One of the main mechanisms for loss of response is the acquisition of molecular mutations that confer drug resistance to FLT3 inhibitors. TP-0903 is an oral multi-kinase inhibitor with activity against FLT3 and several other kinases known to mediate drug resistance. Three heavily treated relapsed/refractory AML patients with FLT3-ITD were treated with TP-0903 50 mg daily, on a phase 1b/2 clinical trial, for as long as disease response or clinical benefit was observed. The dose for one patient was reduced to 37 mg daily mid-cycle after developing grade 3 nausea that improved to grade 2 within 24 h of holding doses of TP-0903. All patients achieved stable disease; however, a significant reduction in bone marrow blast percentage after one to two cycles of treatment was observed in two patients, which correlated with a decrease in FLT3-ITD allelic ratio and variant allele frequency of co-occurring mutations (e.g., NPM1 and DNMT3A). TP-0903 was feasible with no unusual toxicity signals. Additional preclinical and clinical studies are needed in order to determine the role of TP-0903 in AML.Clinical Trial RegistrationClinicalTrials.gov, identifier NCT04518345. |
| format | Article |
| id | doaj-art-3f64ca4dbbe8436d9bea96d14ab5e96b |
| institution | DOAJ |
| issn | 2813-3935 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Hematology |
| spelling | doaj-art-3f64ca4dbbe8436d9bea96d14ab5e96b2025-08-20T03:14:53ZengFrontiers Media S.A.Frontiers in Hematology2813-39352025-04-01410.3389/frhem.2025.15547641554764Preliminary clinical activity of TP-0903 in relapsed or refractory acute myeloid leukemia with FLT3-ITD mutationsBhavana Bhatnagar0Daelynn R. Buelow1Kaitlyn M. Dvorak-Kornaus2Shelley J. Orwick3Jae Yoon Jeon4Zahra Talebi5Amy S. Ruppert6James S. Blachly7Uma Borate8Sharyn D. Baker9Department of Hematology and Medical Oncology, Wheeling Hospital, West Virginia University Cancer Institute, Wheeling, WV, United StatesDivision of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH, United StatesDivision of Hematology, Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, OH, United StatesDivision of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH, United StatesDivision of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH, United StatesDivision of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH, United StatesDivision of Hematology, Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, OH, United StatesDivision of Hematology, Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, OH, United StatesDivision of Hematology, Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, OH, United StatesDivision of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH, United StatesAcute myeloid leukemia (AML) patients with FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) experience shorter disease-free survival and high relapse rates even with FLT3 inhibitor therapy. One of the main mechanisms for loss of response is the acquisition of molecular mutations that confer drug resistance to FLT3 inhibitors. TP-0903 is an oral multi-kinase inhibitor with activity against FLT3 and several other kinases known to mediate drug resistance. Three heavily treated relapsed/refractory AML patients with FLT3-ITD were treated with TP-0903 50 mg daily, on a phase 1b/2 clinical trial, for as long as disease response or clinical benefit was observed. The dose for one patient was reduced to 37 mg daily mid-cycle after developing grade 3 nausea that improved to grade 2 within 24 h of holding doses of TP-0903. All patients achieved stable disease; however, a significant reduction in bone marrow blast percentage after one to two cycles of treatment was observed in two patients, which correlated with a decrease in FLT3-ITD allelic ratio and variant allele frequency of co-occurring mutations (e.g., NPM1 and DNMT3A). TP-0903 was feasible with no unusual toxicity signals. Additional preclinical and clinical studies are needed in order to determine the role of TP-0903 in AML.Clinical Trial RegistrationClinicalTrials.gov, identifier NCT04518345.https://www.frontiersin.org/articles/10.3389/frhem.2025.1554764/fullacute myeloid leukemiaAMLrelapsed/refractoryclinical trialTP-0903 |
| spellingShingle | Bhavana Bhatnagar Daelynn R. Buelow Kaitlyn M. Dvorak-Kornaus Shelley J. Orwick Jae Yoon Jeon Zahra Talebi Amy S. Ruppert James S. Blachly Uma Borate Sharyn D. Baker Preliminary clinical activity of TP-0903 in relapsed or refractory acute myeloid leukemia with FLT3-ITD mutations Frontiers in Hematology acute myeloid leukemia AML relapsed/refractory clinical trial TP-0903 |
| title | Preliminary clinical activity of TP-0903 in relapsed or refractory acute myeloid leukemia with FLT3-ITD mutations |
| title_full | Preliminary clinical activity of TP-0903 in relapsed or refractory acute myeloid leukemia with FLT3-ITD mutations |
| title_fullStr | Preliminary clinical activity of TP-0903 in relapsed or refractory acute myeloid leukemia with FLT3-ITD mutations |
| title_full_unstemmed | Preliminary clinical activity of TP-0903 in relapsed or refractory acute myeloid leukemia with FLT3-ITD mutations |
| title_short | Preliminary clinical activity of TP-0903 in relapsed or refractory acute myeloid leukemia with FLT3-ITD mutations |
| title_sort | preliminary clinical activity of tp 0903 in relapsed or refractory acute myeloid leukemia with flt3 itd mutations |
| topic | acute myeloid leukemia AML relapsed/refractory clinical trial TP-0903 |
| url | https://www.frontiersin.org/articles/10.3389/frhem.2025.1554764/full |
| work_keys_str_mv | AT bhavanabhatnagar preliminaryclinicalactivityoftp0903inrelapsedorrefractoryacutemyeloidleukemiawithflt3itdmutations AT daelynnrbuelow preliminaryclinicalactivityoftp0903inrelapsedorrefractoryacutemyeloidleukemiawithflt3itdmutations AT kaitlynmdvorakkornaus preliminaryclinicalactivityoftp0903inrelapsedorrefractoryacutemyeloidleukemiawithflt3itdmutations AT shelleyjorwick preliminaryclinicalactivityoftp0903inrelapsedorrefractoryacutemyeloidleukemiawithflt3itdmutations AT jaeyoonjeon preliminaryclinicalactivityoftp0903inrelapsedorrefractoryacutemyeloidleukemiawithflt3itdmutations AT zahratalebi preliminaryclinicalactivityoftp0903inrelapsedorrefractoryacutemyeloidleukemiawithflt3itdmutations AT amysruppert preliminaryclinicalactivityoftp0903inrelapsedorrefractoryacutemyeloidleukemiawithflt3itdmutations AT jamessblachly preliminaryclinicalactivityoftp0903inrelapsedorrefractoryacutemyeloidleukemiawithflt3itdmutations AT umaborate preliminaryclinicalactivityoftp0903inrelapsedorrefractoryacutemyeloidleukemiawithflt3itdmutations AT sharyndbaker preliminaryclinicalactivityoftp0903inrelapsedorrefractoryacutemyeloidleukemiawithflt3itdmutations |